tbuckley/cabot-search huggingface dataset:
Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea — STD Surveillance Network, United States, 2016
Authors: Emily J. Weston, Kimberly Workowski, Elizabeth Torrone, Hillard Weinstock, Mark R. Stenger
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

Gonorrhea, the sexually transmitted disease (STD) caused by Neisseria gonorrhoeae, is the second most common notifiable disease in the United States after chlamydia; 468,514 cases were reported to state and local health departments in 2016, an increase of 18.5% from 2015 (1). N. gonorrhoeae has progressively developed resistance to most antimicrobials used to treat the infection (2). As a result, CDC recommends two antimicrobials (250 mg of ceftriaxone [IM] plus 1 g of azithromycin [PO]) for treating uncomplicated gonorrhea to improve treatment efficacy and, potentially, to slow the emergence and spread of antimicrobial resistance. To monitor adherence to the current CDC-recommended regimen for uncomplicated gonorrhea, CDC reviewed enhanced data collected on a random sample of reported cases of gonorrhea in seven jurisdictions participating in the STD Surveillance Network (SSuN) and estimated the proportion of patients who received the CDC-recommended regimen for uncomplicated gonorrhea, by patient characteristics and diagnosing facility type. In 2016, the majority of reported patients with gonorrhea (81%) received the recommended regimen. There were no differences in the proportion of patients receiving the recommended regimen by age or race/ethnicity; however, patients diagnosed with gonorrhea in STD (91%) or family planning/reproductive health (94%) clinics were more likely to receive this regimen than were patients diagnosed in other provider settings (80%). These data document high provider adherence to CDC gonorrhea treatment recommendations in specialty STD clinics, indicating high quality of care provided in those settings. Local and state health departments should monitor adherence with recommendations in their jurisdictions and consider implementing interventions to improve provider and patient compliance with gonorrhea treatment recommendations where indicated.
Social Security and Disability Due to Mental Impairment in Adults
Authors: Howard H. Goldman, William D. Frey, Jarnee K. Riley
Journal: Annual Review of Clinical Psychology (2018)

The Social Security Administration (SSA) oversees two disability programs, Social Security Disability Insurance (SSDI) and Supplemental Security Income (SSI). Adults with mental impairments represent a very large component of the programs. Policy makers and SSA are concerned about the accuracy of disability determination and also about low levels of labor force participation among individuals with disabilities. Adults with mental impairments are challenging to assess for work-related functional limitations. They are also a challenge to return to labor force participation. SSA has sponsored several demonstration research programs focusing on improving the accuracy of disability determination and on interventions in supported employment to return individuals with mental impairments to competitive employment. This article reviews the demonstration research focused on both entry into the disability system (at the “front door”) and potential exit from it (through the “back door”). All of the research holds promise to “right-size” the SSA disability program.
The paracrine effect of visceraladipose tissue obtained at bariatric surgery on primary human hepatic stellatecells grown in human 3D healthy liver scaffolds
Authors: Z. Zhang, L. Meelberghs, L. Frenguelli, W. Al-Akkad, H. Korf, D. Cassiman, G. Mazza, M. Pinzani, K. Rombouts, S. Van Der Merwe
Journal: Journal of Hepatology (2018)
Real‐Time Imaging of Brain Tumor for Image‐Guided Surgery
Authors: Shuang Hu, Homan Kang, Yoonji Baek, Georges El Fakhri, Anren Kuang, Hak Soo Choi
Journal: Advanced Healthcare Materials (2018)

Abstract The completion of surgical resection is a key prognostic factor in brain tumor treatment. This requires surgeons to identify residual tumors in theater as well as to margin the proximity of the tumor to adjacent normal tissue. Subjective assessments, such as texture palpation or visual tissue differences, are commonly used by oncology surgeons during resection to differentiate cancer lesions from normal tissue, which can potentially result in either an incomplete tumor resection, or accidental removal of normal tissue. Moreover, malignant brain tumors are even more difficult to distinguish from normal brain tissue, and resecting noncancerous tissue may create neurological defects after surgery. To optimize the resection margin in brain tumors, a variety of intraoperative guidance techniques are developed, such as neuronavigation, magnetic resonance imaging, ultrasound, Raman spectroscopy, and optical fluorescence imaging. When combined with appropriate contrast agents, optical fluorescence imaging can provide the neurosurgeon real‐time image guidance to improve resection completeness and to decrease surgical complications.
Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups
Authors: Sandra R. Wilson, Robert A. Wise, Mario Castro, Michael J. Mulligan, Estela Ayala, Alan Chausow, Qiwen Huang, Santosh Gummidipundi
Journal: Journal of Allergy and Clinical Immunology (2018)
Proteasome‐mediated proteostasis: Novel medicinal and pharmacological strategies for diseases
Authors: Ribhav Mishra, Arun Upadhyay, Vijay Kumar Prajapati, Amit Mishra
Journal: Medicinal Research Reviews (2018)

Abstract Proteins actively participate in a wide range of cellular physiological functions. But aggregation of proteins results in cytotoxicity, and unwanted aggregation of misfolded proteins often causes many diseases. During abnormal protein aggregation events, cells try to cope against such deleterious consequences because of the remarkable functional attempts of two distinct proteolytic mechanisms. These tightly regulative and signaling mechanisms are autophagy pathway and ubiquitin proteasome system. Proteasome complex system holds the elimination capacity of intracellular aberrant protein aggregation. Despite the considerable progress that has been achieved, which elucidates wide function and diverse roles of proteasome system, still several crucial problems remain unanswered. For example, how the complex proteasomes assembly and their interactive pathways determine the precise sense of several proteotoxic insults, which can severely affect the cell survival and homeostasis? The specific degradation of various aberrant proteins that can disturb cellular homeostasis is achieved by proper proteasome functionality, which is yet another unclear and critical challenge. Therefore, a better understanding of the various cellular signaling mechanisms composing the proteasome machinery carries broad therapeutic implications linked with proteopathies. This article signifies the urgent need, which is now crucial for us to improve our understanding of the proteasome architecture, structure, and functions that span multiple level strategies from the molecular level to the cellular level. This systematic in‐depth information of proteasome may be helpful in the near future to design a new molecular framework based on intrinsic and extrinsic cellular mechanisms that drive the assembly of proteasome to induce cellular survival against proteostasis imbalance and disease conditions.
Cell therapy for acute liver injury- in vivo efficacy of mesenchymal stromal cells in toxic and immune-mediated murine hepatitis
Authors: M. Alfaifi, V. Vigneswara, N.-T. Luu, C. Baan, M. Hoogduijn, M. Gargesha, D. Roy, S. Elliman, L. O’flynn, G.M. Hirschfield, P.N. Newsome
Journal: Journal of Hepatology (2018)
P564L-cystathionine metabolism by cystathionine gamma lyase generates H2S to preserve endothelial cell function and decelerate atherosclerosis development in humans
Authors: S I Bibli, J Hu, V Randriamboavonjy, M Siragusa, F Sigala, S Zukunft, J Pfeilschifter, I Wittig, A Papapetropoulos, I Fleming
Journal: Cardiovascular Research (2018)

junctions, prior to stretching and enlargement of the endothelial cell, followed by alignment around a larger lumen.Conversely, loss of VE-cadherin and inhibition of actin prevented lumen remodelling.Conclusion: Arterial Flt1 by titrating arterial Vegfa regulates the caliber of arterioles during de novo arteriologenesis involving a unique sequence of collective endothelial cell behaviors and actin remodeling events.Plgf and Vegfb, by shifting the Flt1-Vegfa binding equilibrium toward Vegfa release, promote arteriologenesis.Our model suggests that arterial Flt1 may be used as a local cargo to deliver safe Vegfa dosages in revascularization strategies.
Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy
Authors: Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger
Journal: Hepatology (2018)

Congestive hepatopathy (CH) arises from chronically elevated right-sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma. Currently, there are no evidence-based guidelines to direct appropriate screening or management of patients with CH, partly because of the inability of current clinical tools (serum tests, imaging studies, liver stiffness measurements, and liver biopsy) to accurately estimate hepatic fibrosis or the risk for hepatic decompensation. The Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI) score is the only validated serum-based test to predict clinical outcomes in CH. Noninvasive liver stiffness measurements are proving to be of minimal utility as all patients with CH have elevated values that currently cannot differentiate between congestion and fibrosis. In addition, fibrosis staging by liver biopsy is difficult to standardize because of heterogeneous collagen deposition in CH. Moreover, liver biopsy results have little predictive value for post-heart transplant hepatic outcomes in patients with CH. Evaluating liver nodules and masses is also complicated in CH as the finding of delayed venous washout in nodules is not specific for hepatocellular carcinoma in the background of a congested liver, and these lesions may require biopsy to confirm the diagnosis. The lack of effective clinical tools for predicting liver fibrosis and liver function suggests the need for the development of novel biomarkers in patients with CH to assist in the management of this complicated disease. (Hepatology 2018; 00:000-000).
NHS risks missing out on benefits of genomics, MPs warn
Authors: Gareth Iacobucci
Journal: BMJ (2018)

The advancement of genomic medicine in the NHS is being held back by delays in infrastructure development and reduced training budgets, a committee of MPs has warned.

The report by the House of Commons Science and Technology Committee also warned that public support for deploying the UK’s world leading genomics capabilities in the NHS could waver unless more were done to alleviate ethical concerns about the process and to promote the potential benefits.1

The committee said …
Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results
Authors: James B. Bussel, Donald M Arnold, Nichola Cooper, Alhossain A Khalafallah, Michael Boxer, Darla Liles, Waleed Ghanima, Keith McCrae, Hany Zayed, Benoit Cadieux, Anne-Marie Duliege
Journal: Blood (2017)
Profilin-mediated food-induced allergic reactions are associated with oral epithelial remodeling
Authors: Domenico Rosace, Cristina Gomez-Casado, Paloma Fernandez, Marina Perez-Gordo, María del Carmen Dominguez, Angel Vega, María Teresa Belver, Tania Ramos, Francisco Vega, Guadalupe Marco, Manuel de Pedro, Leticia Sanchez, María de las Mercedes Arnas, Marcela Santaolalla, Miguel Ángel Saez, Sara Benedé, Montserrat Fernandez-Rivas, Carlos Blanco, Maria Isabel Alvarado, María M. Escribese, Domingo Barber
Journal: Journal of Allergy and Clinical Immunology (2018)
Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients
Authors: Hui-Han Hu, Jessica Liu, Chia-Ling Chang, Chin-Lan Jen, Mei-Hsuan Lee, Sheng-Nan Lu, Li-Yu Wang, Yuan Quan, Ning-Shao Xia, Chien-Jen Chen, Pei-Jer Chen, Hwai-I Yang
Journal: Clinical Gastroenterology and Hepatology (2018)
Correction: Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria
Authors: J Spelbrink, F.-Y Li, V Tiranti, K Nikali, Q.-P Yuan, M Tariq, S Wanrooij, N Garrido, G Comi, L Morandi, L Santoro, A Toscano, G.-M Fabrizi, H Somer, R Croxen, D Beeson, J Poulton, A Suomalainen, H Jacobs, M Zeviani, C Larsson
Journal: Nature Genetics (2001)
Virological heterogenity of hepatitis delta among Vietnamese populations
Authors: T.B. Mai, X.H. Nghiem, T.S. Bui, M.H. Nguyen, P.G. Dao, L.T. Nguyen, H.S. Le, C.-T. Bock, H. Wedemeyer, T.P. Velavan
Journal: Journal of Hepatology (2018)
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation
Authors: Ana M. Moreno, Xin Fu, Jie Zhu, Dhruva Katrekar, Yu-Ru V. Shih, John Marlett, Jessica Cabotaje, Jasmine Tat, John Naughton, Leszek Lisowski, Shyni Varghese, Kang Zhang, Prashant Mali
Journal: Molecular Therapy (2018)

Development of efficacious in vivo delivery platforms for CRISPR-Cas9-based epigenome engineering will be critical to enable the ability to target human diseases without permanent modification of the genome. Toward this, we utilized split-Cas9 systems to develop a modular adeno-associated viral (AAV) vector platform for CRISPR-Cas9 delivery to enable the full spectrum of targeted in situ gene regulation functionalities, demonstrating robust transcriptional repression (up to 80%) and activation (up to 6-fold) of target genes in cell culture and mice. We also applied our platform for targeted in vivo gene-repression-mediated gene therapy for retinitis pigmentosa. Specifically, we engineered targeted repression of Nrl, a master regulator of rod photoreceptor determination, and demonstrated Nrl knockdown mediates in situ reprogramming of rod cells into cone-like cells that are resistant to retinitis pigmentosa-specific mutations, with concomitant prevention of secondary cone loss. Furthermore, we benchmarked our results from Nrl knockdown with those from in vivo Nrl knockout via gene editing. Taken together, our AAV-CRISPR-Cas9 platform for in vivo epigenome engineering enables a robust approach to target disease in a genomically scarless and potentially reversible manner. Development of efficacious in vivo delivery platforms for CRISPR-Cas9-based epigenome engineering will be critical to enable the ability to target human diseases without permanent modification of the genome. Toward this, we utilized split-Cas9 systems to develop a modular adeno-associated viral (AAV) vector platform for CRISPR-Cas9 delivery to enable the full spectrum of targeted in situ gene regulation functionalities, demonstrating robust transcriptional repression (up to 80%) and activation (up to 6-fold) of target genes in cell culture and mice. We also applied our platform for targeted in vivo gene-repression-mediated gene therapy for retinitis pigmentosa. Specifically, we engineered targeted repression of Nrl, a master regulator of rod photoreceptor determination, and demonstrated Nrl knockdown mediates in situ reprogramming of rod cells into cone-like cells that are resistant to retinitis pigmentosa-specific mutations, with concomitant prevention of secondary cone loss. Furthermore, we benchmarked our results from Nrl knockdown with those from in vivo Nrl knockout via gene editing. Taken together, our AAV-CRISPR-Cas9 platform for in vivo epigenome engineering enables a robust approach to target disease in a genomically scarless and potentially reversible manner.
Noninvasive mapping of fibrosis and inflammation in nonalcoholic fatty liver disease: isolating fibrogenesis in the Space of Disse with MRI R2 multicomponent relaxometry
Authors: P. Clark, W. Chua-Anusorn, C. Oliveira, M. Rocha, F.J. Carrilho, F. Lima, V. Alves, B. Oliveira, H.L. Filho
Journal: Journal of Hepatology (2018)
EXPLORE: A prospective, multinational natural history study of patients with acute hepatic porphyria with recurrent attacks
Authors: L. Gouya, J. Bloomer, M. Balwani, D.M. Bissell, D. Rees, U. Stölzel, J. Phillips, R.K. Kauppinen, J.L. Langendonk, R. Desnick, J.C. Deybach, H. Bonkovsky, C. Parket, H. Naik, M. Badminton, P. Stein, E. Minder, J. Windyga, P. Martasek, M.D. Cappellini, P. Ventura, E. Sardh, P. Harper, S. Sandberg, A. Aarsand, F. Alegre, A. Ivanova, S. Rock, A. Chan, W. Querbes, C. Penz, A. Simon, K. Anderson
Journal: Journal of Hepatology (2018)
Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
Authors: Marco Trevisan, Pietro de Deco, Hairong Xu, Marie Evans, Bengt Lindholm, Rino Bellocco, Peter Barany, Tomas Jernberg, Lars H. Lund, Juan J. Carrero
Journal: European Journal of Heart Failure (2018)

Background Concerns for hyperkalaemia limit the use of mineralocorticoid receptor antagonists (MRAs). The frequency of MRA‐associated hyperkalaemia in real‐world settings and the extent of subsequent MRA discontinuation are poorly quantified. Methods and results Observational study including all Stockholm citizens initiating MRA therapy during 2007–2010. Hyperkalaemias were identified from all potassium (K + ) measurements in healthcare. MRA treatment lengths and dosages were obtained from complete collection of pharmacy dispensations. We assessed the 1‐year incidence and clinical hyperkalaemia predictors, and quantified drug prescription changes after an episode of hyperkalaemia. Overall, 13 726 new users of MRA were included, with median age of 73 years, 53% women and median plasma K + of 3.9 mmol/L. Within a year, 18.5% experienced at least one detected hyperkalaemia (K + &gt; 5.0 mmol/L), the majority within the first 3 months of therapy. As a comparison, hyperkalaemia was detected in 6.4% of propensity‐matched new beta‐blocker users. Chronic kidney disease (CKD), older age, male sex, heart failure, peripheral vascular disease, diabetes and concomitant use of angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, beta‐blockers and diuretics were associated with increased hyperkalaemia risk. After hyperkalaemia, 47% discontinued MRA and only 10% reduced the prescribed dose. Discontinuation rates were higher after moderate/severe (K + &gt; 5.5 mmol/L) and early in therapy (&lt;3 months from initiation) hyperkalaemias. CKD participants carried the highest risk of MRA discontinuation in adjusted analyses. When MRA was discontinued, most patients (76%) were not reintroduced to therapy during the subsequent year. Conclusion Among real‐world adults initiating MRA therapy, hyperkalaemia was very common and frequently followed by therapy interruption, especially among participants with CKD.
Abstract 13512: Chemokines and Carotid Intima-Media Thickness in a European Population at High Risk for Cardiovascular Events: Results From the IMPROVE Study
Authors: Ilais Moreno Velasquez, Anders Malarstig, Rona J Strawbridge, Damiano Baldassarre, Fabrizio Veglia, Karin Leander, Angela Silveira, Rainer Rauramaa, Andries J Smit, Philippe Giral, Elmo Mannarino, Elena Tremoli, Steve E Humphries, Anders Lindén, Anders Hamsten, Ulf de Faire, Bruna Gigante
Journal: Circulation (2016)

Background: Experimental studies indicate that two archetype chemokines circulating in the blood, IL-8 and GRO-α, are critical for atherogenesis. However, their association with measures of subclinical atherosclerosis has not been investigated. Hypothesis: Here we test the hypothesis that circulating IL8 and GRO-α protein are associated with the carotid artery intima media thickness (c-IMT) in a large European multicenter study: the c-IMT and c-IMT Progression as Predictors of Vascular Events in a High Risk European Population ( IMPROVE ) study . Methods: IMPROVE study participants (n=3,703), recruited in 5 European Countries (Sweden, Finland, the Netherlands, France and Italy), had at least three cardiovascular (CV) risk factors but not prevalent CV diseases. C-IMT measures (mm) (c-IMT mean , c-IMT max and c-IMT mean-max ) were recorded at baseline. Each measurement represent the average of 8 (4 left and 4 right) carotid segments. IL8 and GRO-α were measured in plasma from 3,452 participants (women, n=1,784; men, n=1,668) using the Olink ProSeek CVD array I and expressed in arbitrary units. We evaluated the association, expressed as beta coefficient (β) and 95% confidence intervals (CI), between chemokines and c-IMT using median regression. Models were adjusted by sex, age, body mass index, hypertension, diabetes, current smokers, hypercholesterolemia and latitude. Results: Higher levels of IL8 and GRO-α were observed in participants from Northern Europe as compared to those from Southern Europe [IL8: 50 (41-62) vs 36 (28-49) and GRO-α 108 (70-176) vs 42(22-95)]. At multivariable analysis only in men, levels of IL8 were positively associated with c-IMT measures: c-IMT mean [1.0 x 10 -4 (6.5 x 10 -5 -1.4 x 10 -4 ), p&lt;0.01], c-IMT max [(6.5 x 10 -4 ,(4.8 x 10 -4 -8.2 x 10 -4 ), p&lt;0.01] and c-IMT mean-max [1.7 x 10 -4 , (1.3 x 10 -4 -2.2 x 10 -4 ), p&lt;0.01]. No corresponding association was observed for GRO-α and c-IMT measurements. Conclusions: The chemokine IL8, but not GRO-α, was associated with baseline c-IMT in men at high risk of CV events. Furthermore, our results suggest the presence of a European north-to-south gradient in chemokine levels. New studies are warranted to disentangle potential differences between IL8 and CV risk across sexes.
Recurrence of hepatocellular carcinoma in patients with a history of HCC after SVR to DAA for chronic hepatitis C
Authors: I. Ozeki, H. Suii, R. Tatsumi, M. Yamaguchi, M. Kimura, T. Arakawa, Y. Kuwata, T. Ohmura, S. Hige, Y. Karino, J. Toyota
Journal: Journal of Hepatology (2018)
P334The efficiency of autologous bone marrow stem cells in STEMI patients with systolic dysfunction- ECG-gated SPECT myocardial perfusion and echocardiography approach
Authors: N M Popa-Fotea, M M Micheu, G Nicula, N Oprescu, A Scarlatescu, L Calmac, M Dorobantu
Journal: Cardiovascular Research (2018)